Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PIMCO Tactical Income Units Class A T.PTI


Primary Symbol: T.PMEI.UN Alternate Symbol(s):  PTIUF

PIMCO Dynamic Income Opportunities Fund (the Fund) is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by utilizing a dynamic asset allocation strategy among multiple fixed income sectors in the global credit markets, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed-, variable- and floating-rate income-producing securities of United States and foreign issuers, including emerging market issuers. The Fund may invest without limitation in investment grade debt obligations and below investment grade debt obligations (high yield securities or junk bonds), including securities of stressed, distressed or defaulted issuers. The Fund's investment manager is Pacific Investment Management Company LLC.


TSX:PMEI.UN - Post by User

Post by mark5698on Nov 23, 2004 11:36am
335 Views
Post# 8214636

New JV partner for Patheon ...

New JV partner for Patheon ...Kosmos Pharma MOVA Pharmaceutical Corporation And Kosmos Pharma To Jointly Develop PHARMACEUTICAL Uses For Quick Dissolve Film CAGUAS, Puerto Rico, and GREAT FALLS, Va., Sept. 4 /PRNewswire/ -- MOVA Pharmaceutical Corporation and Kosmos Pharma Limited have reached an agreement in principle to commercialize pharmaceutical and non-pharmaceutical quick dissolve film delivery systems. This novel technology would be available to pharmaceutical companies and others as a new platform for drug development. The increasing role of quick dissolve film applications for the oral delivery of products is evidenced by the overwhelming consumer acceptance of breath freshener applications worldwide. In the pharmaceutical industry, quick dissolve film represents the next paradigm in drug delivery technology. This agreement brings together Kosmos' proprietary FDTAP(TM) film technology, with the development and manufacturing capabilities of MOVA Pharmaceutical. "This agreement represents the beginning of the commercialization of quick dissolve film's use for a broad array of pharmaceuticals, and revolutionizes the delivery of oral pharmaceuticals. We are very proud of having reached this strategic alliance with the people of MOVA, who have a proven track record as one of the best pharmaceutical contract manufacturing companies in the business," said Richard C. Fuisz, M.D., chairman of Kosmos Pharma. Joaquin B. Viso, president and chairman of the board of MOVA Pharmaceutical, indicated that, "This is the result of our continuous effort to offer new technologies and services to our customers in the pharmaceutical industry. Kosmos has a very strong technology background and we are very pleased to join forces with them for the commercialization of this important and innovative new drug delivery system." Kosmos Pharma is a leading oral drug delivery company. Kosmos' core technology, FDTAB(TM), is a film-based oral dosage form that quickly dissolves on the tongue, similar to currently marketed film-based breath freshener products. Kosmos' founder, Richard C. Fuisz, M.D., previously founded Fuisz Technologies, a publicly-traded drug delivery company acquired by Biovail in 1999. Founded in 2000, Kosmos is a private company with corporate offices in Northern Virginia and research facilities in Bristol, Tennessee. Established in 1986, MOVA Pharmaceutical Corporation is the United States' first company dedicated to the large-scale contract manufacturing of pharmaceutical finished products, a field in which it has become a recognized leader. MOVA has earned the trust of leading pharmaceutical companies and believes in establishing long-term relationships with its clients. Its flexible approach to tailor services to client needs and wide range of capabilities make it the "right hand in outsourcing" for the industry. The company operates manufacturing facilities in Caguas, Carolina and Manati, Puerto Rico, as well as a Research and Development Center in Caguas. MAKE YOUR OPINION COUNT - Click Here SOURCE Kosmos Pharma Limited -0- 09/04/2002 /CONTACT: Jose E. Casellas, Vice President Business Development of MOVA Pharmaceutical Corporation, +1-787-258-1661, Fax: +1-787-258-1794, or e-mail: jose.casellas@movapharm.com; or Joseph M. Fuisz, Esq., Vice President of Kosmos Pharma Limited, +1-703-759-1006, Fax: +1-703-759-1009, or e-mail: jfuisz@kosmospharma.com/ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Good luck to all
Bullboard Posts